Beacon Pointe Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Beacon Pointe Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-636	Closed	-$16K	–	1065
2022 Q2	$16K	Hold	636	–	–	﹤0.01%	1034
2022 Q1	$24K	Hold	636	–	–	﹤0.01%	1179
2021 Q4	$37K	Hold	636	–	–	﹤0.01%	918
2021 Q3	$52K	Hold	636	–	–	﹤0.01%	889
2021 Q2	$60K	Buy	+636	New	+$47.1K	﹤0.01%	817

Other funds holding VTGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Beacon Pointe Advisors's VTGN Position: Q3 2022 in Review

Beacon Pointe Advisors sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 636 shares — an estimated $16K sold.

Beacon Pointe Advisors first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $60K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

Beacon Pointe Advisors reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
Beacon Pointe Advisors sold 636 VistaGen Therapeutics shares in Q3 2022, an estimated $16K.
Beacon Pointe Advisors first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
Beacon Pointe Advisors's VistaGen Therapeutics position peaked at $60K in Q2 2021.
92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Beacon Pointe Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.